News Release Details
Rocket Pharmaceuticals Prices Public Offering of Common Stock
Nov 27, 2018
|
All the shares in the offering are to be sold by Rocket. The offering is
expected to close on or about
BofA Merrill Lynch, Cowen and Evercore ISI are acting as joint
book-running managers for the offering.
In addition to the shares sold in the public offering, Rocket announced
the concurrent sale of 967,742 shares of common stock at a price of
The public offering is being made by Rocket pursuant to an effective
shelf registration statement on Form S-3 that was previously filed with
the
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-looking Statements
Various statements in this release concerning Rocket’s future
expectations, plans and prospects, including without limitation,
Rocket’s expectations regarding the consummation of the offerings and
the satisfaction of customary closing conditions with respect to the
offerings and the anticipated use of the net proceeds of the offerings,
may constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of
1995 and other federal securities laws and are subject to substantial
risks, uncertainties and assumptions. You should not place reliance on
these forward-looking statements, which often include words such as
“anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“seek,” “should,” “suggest,” “target,” “will,” “will give,” “would,” or
similar terms, variations of such terms or the negative of those terms.
Although Rocket believes that the expectations reflected in the
forward-looking statements are reasonable, Rocket cannot guarantee such
outcomes. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including, without limitation, changes as a result of market
conditions or for other reasons, the risk that the offerings will not be
consummated, and the impact of general economic, industrial or political
conditions in
View source version on businesswire.com: https://www.businesswire.com/news/home/20181127005908/en/
Source:
Claudine Prowse, Ph.D.
SVP Corporate Development and IRO
Rocket
Pharmaceuticals, Inc.
The Empire State Building, Suite 7530
New
York, NY 10118
www.rocketpharma.com
investors@rocketpharma.com